RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.
External link for RAGE Biotech
Melbourne, AU
RAGE Biotech reposted this
Join us at the leading edge of RNA therapeutics. RAGE Biotech is seeking a Research Assistant or Research Officer with to join our new lab at the Jumar Bioincubator in Melbourne. See the job post https://lnkd.in/gWnwCws3 for more details on this rare opportunity.
Join us at the leading edge of RNA therapeutics. RAGE Biotech is seeking a Research Assistant or Research Officer with to join our new lab at the Jumar Bioincubator in Melbourne. See the job post https://lnkd.in/gWnwCws3 for more details on this rare opportunity.
RAGE Biotech has been selected as a Featured Company at the American Thoracic Society Respiratory Innovation Summit. The RIS is a unique forum, a concentrated gathering of key influencers in respiratory health innovation, with representatives from major stakeholders: innovators, pharma companies, investors, thought leaders, and most important, patient groups. For more on the ATS-RIS, you can check the news page on our website. We are particularly honoured and grateful to be selected for the second year in a row and we’re looking forward to sharing our progress on our life-changing RNA therapeutics for chronic lung disease. If you’re at ATS2024 in San Diego, we’ll be at the RIS all day Saturday May 18. See you there!
RAGE Biotech is gearing up to become a clinical stage company, today announcing two key clinical leadership appointments. We are delighted to let you know that Aili Lazaar has joined as Chief Medical Officer. Dr Lazaar was previously Director, Discovery Medicine at GSK for 18 years, specialising in early-phase development in respiratory medicines, and we are fortunate indeed to have Aili’s experience to guide our clinical strategy. We are also very pleased to announce that Nicole Kruger is bringing her deep biotech and pharma clinical trial operations skills to RAGE as our recently appointed Director Clinical Operations. Read more on our updated website, and join us in welcoming Aili and Nic!
Our CEO recently presented an overview of approved oligonucleotide medicines and discussed how splice-switching oligonucleotides (SSOs) fit into the mRNA medicine platform. He also gave a guided tour through RAGE Biotech’s genesis, our own innovative SSO technology, and how we are applying it to improve the lives of patients with difficult-to-treat chronic inflammatory disease. Chris was one of three invited speakers in mRNA Victoria and BioMelbourne Network’s outstanding mRNA Lecture Series. Series 2, Lecture One, ‘The RNA Platform: The Breadth of Possibility Beyond mRNA’, was held on Friday 10 November 2023, and mRNA Vic have just released a recording of the session at https://lnkd.in/gbHZ-K7F
We are pleased to let you know that Louis Pymar has joined the Board of RAGE Biotech. Dr Pymar is a Senior Commercialisation Manager in the Office of Industry and Commercial Development at the University of Western Australia (UWA) and his bio is on our updated website. Welcome Louis! UWA’s founding Director representative Samantha South has vacated her position to focus on her outside senior executive roles. We are very grateful for Dr South’s Directorship since the incorporation of RAGE Biotech and wish her great success. Thank you Samantha!